Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Cardiac Sciences
    • PCSK9 inhibitor...

    PCSK9 inhibitor Evolocumab safely cuts LDL cholesterol across all stages of CKD

    Written by Deepanjana Sarkar Published On 2019-06-17T20:20:46+05:30  |  Updated On 17 Jun 2019 8:20 PM IST
    PCSK9 inhibitor Evolocumab safely cuts LDL cholesterol across all stages of CKD

    PCSK9 inhibitor, Evolocumab is clinically effective and safe for lowering Low-density lipoprotein cholesterol, LDL cholesterol levels across all stages of chronic kidney disease, CKD, revealed a FOURIER trial. The study has been published in the Journal of the American College of Cardiology.


    PCSK9 inhibitors are a new class of drugs that lower Low-density lipoprotein, LDL, or “bad,” cholesterol. Right now, there are two FDA-approved medications: alirocumab and evolocumab to achieve this goal. Studies show that PCSK9 inhibitors have a powerful effect and in some cases can actually prevent heart attacks or strokes but their safety in end-stage renal disease is not known.


    FOURIER trial referred to as Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk, was conducted to compare outcomes with evolocumab and placebo according to kidney function.


    The risk of adverse cardiovascular outcomes is high in patients with chronic kidney disease CKD despite the availability of lipid lowing drugs. The ability of statins, the most widely used agents, to lower the risk of cardiovascular death appears to be limited in those with severe CKD requiring renal replacement therapy. Recently, biological agents targeting the proprotein convertase subtilisin–Kexin type 9 (PCSK9) have been shown to reduce low-density lipoprotein cholesterol (LDL-C) by 50% to 60% in addition to background statin and reduce cardiovascular events.


    The FOURIER trial randomized individuals with clinically evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dl or non–high-density lipoprotein cholesterol ≥100 mg/dl to evolocumab or placebo. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization), key secondary endpoint (cardiovascular death, myocardial infarction, or stroke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-epidemiology estimated glomerular filtration rate.


    Key findings of the study




    • There were 8,077 patients with preserved kidney function, 15,034 with stage 2 CKD, and 4,443 with ≥stage 3 CKD.

    • Low-density lipoprotein cholesterol, LDL-C reduction with evolocumab compared with placebo at 48 weeks was similar across CKD groups at 59%, 59%, and 58%, respectively.

    • Relative risk reduction for the primary endpoint was similar for preserved function, and stage ≥3 CKD.

    • Relative risk reduction for the secondary endpoint was similar across CKD stages.

    • Absolute RRs at 30 months for the secondary endpoint was −2.5% for stage ≥3 CKD compared with −1.7% with preserved kidney function.

    • Adverse events, including estimated glomerular filtration rate decline, were infrequent and similar regardless of CKD stage.


    The authors concluded that Low-density lipoprotein cholesterol, LDL-cholesterol lowering and relative clinical efficacy and safety of evolocumab versus placebo were consistent across CKD groups. The absolute reduction in the composite of cardiovascular death, MI, or stroke with evolocumab was numerically greater with more advanced CKD.


    For further reference, click on the link

    DOI: 10.1016/j.jacc.2019.03.513
    cardiovascular deathcardiovascular eventscardiovascular outcomescholesterolCKDCoronary RevascularizationdrugsevolocumabFOURIER trialHospitalizationhyperlipidemiaJournal of the American College of CardiologylipidLipoproteinMedical newsmedical news indiamyocardial infarctionPCSK9PCSK9 inhibitionplaceboproproteinProprotein convertase subtilsin-kexin type 9statinsstroke

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Deepanjana Sarkar
    Deepanjana Sarkar
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok